

REMARKS***Acknowledgment of the Examiner's Withdrawal of Certain Rejections and Objections and Indication of Allowable Subject Matter***

Applicants gratefully acknowledge the Examiner's withdrawal of the following rejections: (a) the previous rejection of claims 46-47 under 35 U.S.C. § 112, first paragraph as introducing new matter; (b) the previous objection to claims 47-48 for informalities; (c) the previous rejection of claims 27, 31-32, 38-39, 46 and 49-62 as being as being unpatentable over Ledbetter *et al.* (WO 97/20048, June 5, 1997) in view of Guyre *et al.* (*Cancer Immunol Immunother.* 1997 Nov-Dec;45(3-4):146-8); and (d) the previous rejection of claims 27-30 as being unpatentable over Ledbetter *et al.* (WO 97/20048, June 5, 1997) in view of Guyre *et al.* (*Cancer Immunol Immunother.* 1997 Nov-Dec;45(3-4):146-8) and Fanger *et al.*, (WO 91/00360, January 10, 1991).

Applicants further acknowledge with appreciation the Examiner's indication that claims 27-33, 36-39 and 49-62 are considered allowable and that the application, as a whole, is in condition for allowance, with the exception of formalities regarding the Requirements for a Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, which Applicants address in detail below.

Sequence Requirements

At page 3 of the pending Action, the Examiner has requested compliance with the requirements of 37 C.F.R. §§1.821-1.825.

In response to this request, a replacement Sequence Listing is submitted herewith, which sets forth the nucleotide and amino acids sequences depicted in Figures 4 and 10 and the specification has been amended to insert sequence identifiers where appropriate. Moreover, enclosed herewith is a diskette which contains a replacement Sequence Listing in computer readable form as required by 37 C.F.R. § 1.821(e). Also, enclosed is a paper copy of the Sequence Listing and a statement that the contents of the paper copy and the computer readable copy of the Sequence Listing are the same as required by 37 C.F.R. § 1.821(f). A copy of the


Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures is also enclosed.

CONCLUSION

In view of the above amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney could be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Dated: July 27, 2007

Respectfully submitted,

By 

Jill Gomy Sloper

Registration No.: 60,760

LAHIVE & COCKFIELD, LLP

One Post Office Square

Boston, Massachusetts 02109-2127

(617) 227-7400

(617) 742-4214 (Fax)

Attorney/Agent For Applicants